These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

623 related articles for article (PubMed ID: 22999165)

  • 21. Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study.
    Papademetriou V; Lovato L; Tsioufis C; Cushman W; Applegate WB; Mottle A; Punthakee Z; Nylen E; Doumas M;
    Am J Nephrol; 2017; 45(2):136-145. PubMed ID: 27992863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus.
    Hemmingsen B; Lund SS; Gluud C; Vaag A; Almdal TP; Hemmingsen C; Wetterslev J
    Cochrane Database Syst Rev; 2013 Nov; (11):CD008143. PubMed ID: 24214280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Population-Based Analysis of Quality Indicators in CKD.
    Manns L; Scott-Douglas N; Tonelli M; Weaver R; Tam-Tham H; Chong C; Hemmelgarn B
    Clin J Am Soc Nephrol; 2017 May; 12(5):727-733. PubMed ID: 28377473
    [TBL] [Abstract][Full Text] [Related]  

  • 24. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD.
    Inker LA; Astor BC; Fox CH; Isakova T; Lash JP; Peralta CA; Kurella Tamura M; Feldman HI
    Am J Kidney Dis; 2014 May; 63(5):713-35. PubMed ID: 24647050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KDOQI hypertension, dyslipidemia, and diabetes care guidelines and current care patterns in the United States CKD population: National Health and Nutrition Examination Survey 1999-2004.
    Snyder JJ; Collins AJ
    Am J Nephrol; 2009; 30(1):44-54. PubMed ID: 19202328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality and Renal Outcomes in Patients with Diabetes and Albuminuria: a Systematic Review and Meta-Analysis.
    Wang K; Hu J; Luo T; Wang Y; Yang S; Qing H; Cheng Q; Li Q
    Kidney Blood Press Res; 2018; 43(3):768-779. PubMed ID: 29794446
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials.
    Maione A; Navaneethan SD; Graziano G; Mitchell R; Johnson D; Mann JF; Gao P; Craig JC; Tognoni G; Perkovic V; Nicolucci A; De Cosmo S; Sasso A; Lamacchia O; Cignarelli M; Manfreda VM; Gentile G; Strippoli GF
    Nephrol Dial Transplant; 2011 Sep; 26(9):2827-47. PubMed ID: 21372254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Impact of Physical Activity on Glycemic Variability Assessed by Continuous Glucose Monitoring in Patients With Type 2 Diabetes Mellitus: A Systematic Review.
    Bennetsen SL; Feineis CS; Legaard GE; Lyngbæk MPP; Karstoft K; Ried-Larsen M
    Front Endocrinol (Lausanne); 2020; 11():486. PubMed ID: 32903679
    [No Abstract]   [Full Text] [Related]  

  • 29. Population-Attributable Fractions of Modifiable Lifestyle Factors for CKD and Mortality in Individuals With Type 2 Diabetes: A Cohort Study.
    Dunkler D; Kohl M; Teo KK; Heinze G; Dehghan M; Clase CM; Gao P; Yusuf S; Mann JF; Oberbauer R;
    Am J Kidney Dis; 2016 Jul; 68(1):29-40. PubMed ID: 26830448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial.
    Parvanova A; Trillini M; Podestà MA; Iliev IP; Ruggiero B; Abbate M; Perna A; Peraro F; Diadei O; Rubis N; Gaspari F; Carrara F; Stucchi N; Belviso A; Bossi AC; Trevisan R; Remuzzi G; de Borst M; Ruggenenti P;
    Lancet Diabetes Endocrinol; 2018 Jan; 6(1):27-40. PubMed ID: 29104158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality.
    ; Orchard TJ; Nathan DM; Zinman B; Cleary P; Brillon D; Backlund JY; Lachin JM
    JAMA; 2015 Jan; 313(1):45-53. PubMed ID: 25562265
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypoglycemia, chronic kidney disease, and diabetes mellitus.
    Alsahli M; Gerich JE
    Mayo Clin Proc; 2014 Nov; 89(11):1564-71. PubMed ID: 25305751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence for a dose effect of renin-angiotensin system inhibition on progression of microalbuminuria in Type 2 diabetes: a meta-analysis.
    Blacklock CL; Hirst JA; Taylor KS; Stevens RJ; Roberts NW; Farmer AJ
    Diabet Med; 2011 Oct; 28(10):1182-7. PubMed ID: 21627686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary and Secondary Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease.
    Ali S; Dave N; Virani SS; Navaneethan SD
    Curr Atheroscler Rep; 2019 Jun; 21(9):32. PubMed ID: 31230129
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial.
    Heerspink HJ; Persson F; Brenner BM; Chaturvedi N; Brunel P; McMurray JJ; Desai AS; Solomon SD; Pfeffer MA; Parving HH; de Zeeuw D
    Lancet Diabetes Endocrinol; 2016 Apr; 4(4):309-17. PubMed ID: 26774608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Albuminuria, serum creatinine, and estimated glomerular filtration rate as predictors of cardio-renal outcomes in patients with type 2 diabetes mellitus and kidney disease: a systematic literature review.
    Norris KC; Smoyer KE; Rolland C; Van der Vaart J; Grubb EB
    BMC Nephrol; 2018 Feb; 19(1):36. PubMed ID: 29426298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk Prediction for Early CKD in Type 2 Diabetes.
    Dunkler D; Gao P; Lee SF; Heinze G; Clase CM; Tobe S; Teo KK; Gerstein H; Mann JF; Oberbauer R;
    Clin J Am Soc Nephrol; 2015 Aug; 10(8):1371-9. PubMed ID: 26175542
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.